SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”),
an original equipment manufacturer of silicon nitride ceramic for
medical and non-medical applications, announced new studies
confirming that its material inactivates SARS-CoV-2, the causative
agent of the COVID-19 pandemic, as well as the Influenza A virus
that is responsible for the common cold.
Previous findings had shown that SINTX’s silicon
nitride can inactivate SARS-CoV-2, as well as other single-strand
RNA (ssRNA) viruses such as Influenza A, Feline calicivirus, and
Enterovirus. Those findings were first reported in June 2020 on
BioRxiv, a pre-print server for COVID-19 research ahead of peer
review. Data related to the other ssRNA viruses are under peer
review for publication.
The latest SARS-CoV-2 testing was done at the
National Center for Biodefense and Infectious Diseases, George
Mason University, Virginia (GMU). The study was designed to (1)
reproduce the earlier findings using an independent institution and
study protocol, and (2) show a time-and dose-dependent antiviral
effect of silicon nitride, and (3) establish a U.S.-based testing
facility for future testing of commercial products, such as fabrics
containing silicon nitride.
The GMU data confirm that silicon nitride
strongly inhibits SARS-CoV-2, after just one minute of exposure.
The anti-viral effect increases with higher doses and longer
duration of exposure to silicon nitride. Importantly, silicon
nitride is non-toxic to mammalian cells, a finding that is
consistent with the successful clinical outcomes of SINTX’s spinal
implants made of the same material as was tested at GMU.
Separate testing at another contract research
facility, ImQuest BioSciences, Frederick Maryland, showed that
SINTX’s silicon nitride strongly inactivates the Influenza A virus
as well. Selected data from that testing is shown in the graph
above.
“The ability of silicon nitride to effectively
terminate the SARS-CoV-2 and Influenza A viruses is of importance,
as the world braces for the flu season, with SARS-CoV-2 still
around,” said Dr. Sonny Bal, President, and CEO of SINTX
Technologies. “We are moving at full speed to incorporate silicon
nitride into consumer masks that will catch-and-kill these
respiratory pathogens. Beyond face masks, the antipathogenic
advantages of silicon nitride will benefit schools, nursing homes,
hospitals, casinos, cruise ships, day-care centers, commercial
travel, and many other markets. Our R&D will advance the
science, while external partners develop commercial products.”
“We are excited to get the results from this
study as they solidify what we already know about SINTX and to
continue efforts around bringing a mask to market,” said Bruce
Lorange, CEO of O2TODAY, the company with whom SINTX has entered an
agreement to develop face masks. “The latest data from SINTX is a
solid confirmation of silicon nitride’s promise toward combatting
the spread of COVID-19 and the flu, both of which are global
worries.”
The COVID 19-driven demand for antipathogenic
materials goes beyond face masks. As such, SINTX is identifying new
revenue opportunities in industries such as automotive, aerospace,
biomedicine, and others. The company is in discussions with
prospective partners interested in developing a variety of
products, such as automotive parts, cell phone cases, air filters,
and medical PPE. SINTX looks forward to sharing additional
developments in the coming months.
About SINTX Technologies, Inc.
SINTX Technologies is an OEM ceramics company
that develops and commercializes silicon nitride for medical and
non-medical applications. The core strength of SINTX Technologies
is the manufacturing, research, and development of silicon nitride
ceramics for external partners. The Company presently manufactures
silicon nitride powders and components in its FDA registered and
ISO 13485:2016 certified manufacturing facility.
For more information on SINTX Technologies
or its silicon nitride material platform, please
visit www.sintx.com.
About ImQuest BioSciences Inc.
ImQuest BioSciences, Inc.
(http://imquestbio.com/), based in Frederick, Maryland, is a
contract research organization (CRO) focused on assisting their
biotechnology and pharmaceutical company clients in the development
of agents for the prevention and treatment of infectious disease,
cancer and inflammation. ImQuest’s proprietary ImQuestSUCCESS
platform for virology, microbiology, topical microbicides, and
cancer has assisted their clients in expediting the development of
products for clinical evaluation through rapid identification of
candidates with a high probability of clinical success by reducing
the risk associated with failure experienced during clinical
development.
Forward-Looking Statements
SINTX Technologies: This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 (PSLRA) that are subject
to a number of risks and uncertainties. Risks and uncertainties
that may cause such differences include, among other things; the
collaboration with O2TODAY may not result in the development of any
products; that SINTX has not as yet developed any products with
antiviral properties which incorporate the use of silicon nitride;
products developed under the joint development agreement may not be
effective against the SARS-CoV-2 virus; incorporation of silicon
nitride into personal protective equipment may not be safe or
effective; volatility in the price of SINTX’s common stock; the
uncertainties inherent in new product development, including the
cost and time required to commercialize such product(s); market
acceptance of our products once commercialized; SINTX’s ability to
raise additional funding and other competitive developments.
Readers are cautioned not to place undue reliance on the
forward-looking statements, which speak only as of the date on
which they are made and reflect management’s current estimates,
projections, expectations and beliefs. There can be no assurance
that any of the anticipated results will occur on a timely basis or
at all due to certain risks and uncertainties, a discussion of
which can be found in SINTX’s Risk Factors disclosure in its Annual
Report on Form 10-K, filed with the Securities and Exchange
Commission (SEC) on March 26, 2020, and in SINTX’s other filings
with the SEC. SINTX disclaims any obligation to update any
forward-looking statements. SINTX undertakes no obligation to
publicly revise or update the forward-looking statements to reflect
events or circumstances that arise after the date of this
report.
Business Inquiries for SINTX:SINTX
Technologies801.839.3502IR@sintx.com
Media Inquiries for SINTX: Amanda Barry
Associate Director, Content and PR The Summit Group +1 509.554.8409
abarry@summitslc.com
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Aug 2024 to Sep 2024
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Sep 2023 to Sep 2024